TP53 and cancer: These mutant p53 proteins, such as p53R175H and p53R273H, not only lose their tumour-suppressing functions but can also acquire new oncogenic properties that drive cancer progression [14, 15], although the significance of these gain-of-function effects remain controversial [16–18].